About - Cancer Controls

About Us

Your trusted source for quality diagnostic cancer controls.

With a profound respect for the art and science of good laboratory practice, Cancer Controls brings a thoughtfully curated portfolio of reference standard/control products to diagnostic and research laboratories in the U.S. and Canadian markets. Our select products carry 4 important criteria:

Consistency
Quantitation
Transferability
Patient-likeness

What this could mean for your laboratory:

Consistency
Process control to ensure assay performance over time. More efficient troubleshooting and minimization of downtime.

Quantitation
Improvement in operational rollout and increased confidence in data quality integrated with Quality Standards Bodies’ recommended metrics.

Transferability
Lower validation costs; and reduction in assay to assay and lab to lab discordance.

Patient-likeness
Representation of relevant biology from materials originating from humans and provision of reliable reference standard materials to assess nucleic acid quality, antigen quality, reagent lot variability and instrument or operator performance.

Together with our network of partners

a best-in-class portfolio of cancer control solutions has been collectively assembled to support your routine and custom control requirements to enhance diagnostic accuracy and improve testing for both molecular and tissue pathology.

Pete Bantock

Co-Founder

Pete Bantock is a seasoned business executive with international commercial and general management experience. With a colorful career that spans clinical diagnostics, biotechnology, and pharmaceuticals, he brings an eclectic perspective to commercializing and operationalizing technologies in a variety of healthcare delivery settings. Pete has held a variety of leadership or executive roles at Thermo Fisher Scientific, Accelerate Diagnostics, Roche Tissue Diagnostics and Abbott Diagnostics Division. Pete obtained a Bachelors’ Degree and a Post Graduate Diploma in Education from Rhodes University, South Africa.

Mark Rees, PhD

Co-Founder

Dr. Mark Rees is a visionary strategic thinker with expertise in assay design, standardization, reproducibility, & improved accuracy for translational and clinical pathology. As a seasoned innovator and business leader, Dr. Rees has successfully commercialized several breakthrough platforms, including patented cell line derived faux tissue control technology. This technology has since been adopted by several leading US cancer centers. Dr Rees has held a variety of executive and leadership roles at Ultivue, StatLab, Enzo Lifesciences & Leica Biosystems (Danaher). Dr Rees obtained a PhD, MSc & BSc at the Medical School of the University of Newcastle upon Tyne, England, United Kingdom.